A leader in the research of targeted C3 therapies, Apellis was established in 2009 with the ambition to develop life-changing medicines for people with complement-driven diseases, including those within haematology, ophthalmology, neurology, and nephrology.
Targeting complement proteins centrally at the level of C3 is a novel therapeutic approach that may have potential for treatment of geographic atrophy in age-related macular degeneration.
Visit: apellis.com
